7-Fluoro-6-nitro-1,2,3,4-tetrahydroquinolin-2-one | 1146289-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-Fluoro-6-nitro-1,2,3,4-tetrahydroquinolin-2-one
• 英文别名: 7-fluoro-6-nitro-3,4-dihydro-1H-quinolin-2-one
• CAS: 1146289-84-0
• 化学式: C9H7FN2O3
• mdl: MFCD11857811
• 分子量: 210.16
• InChiKey: KKIGZYNYRMWCLY-UHFFFAOYSA-N

物化性质

• 沸点：
  409.0±45.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：THE TRUSTEES OF PRINCETON UNIVERISTY

  公开号：WO2021151062A1

  公开（公告）日：2021-07-29

  Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).

  本文提供了新颖的杂环化合物，例如具有I、I-P、II、II-P或III式的化合物。本文还提供了包含这些化合物的药物组合物以及使用这些组合物的方法，例如用于抑制醛脱氢酶和/或治疗各种癌症、癌症转移、2型糖尿病、肺动脉高压（PAH）或新生内膜增生（NIH）。
• TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS
  申请人：The Trustees of Princeton University

  公开号：EP3830079A1

  公开（公告）日：2021-06-09
• [EN] TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROQUINOLINO POUR LE TRAITEMENT DE CANCERS MÉTASTATIQUES ET CHIMIORÉSISTANTS
  申请人：UNIV PRINCETON

  公开号：WO2020028461A1

  公开（公告）日：2020-02-06

  Disclosed herein are compounds of Structural Formula I. Compounds of Structural Formula I inhibit aldehyde dehydrogenase isoform Ia3 (ALDHIa3) and are useful for treating cancer, for example, metastatic or chemoresistant cancer, such as metastatic cancer resistant to chemotherapy. Also disclosed herein are compositions comprising compounds of Structural Formula I and uses of compounds of Structural Formula I for treating cancer, for example, metastatic or chemoresistant cancer.